November 18, 2026 · BJOG : an international journal of obstetrics and gynaecology · DOI: 10.1111/1471-0528.70385

Efficacy and Safety of the Oral Gonadotropin-Releasing Hormone Antagonist DW4902 for Heavy Menstrual Bleeding in Uterine Fibroids: A Randomized, Double-Blind, Placebo-Controlled Phase II Trial.

Listen to this summary

This Phase II randomized, double-blind, placebo-controlled trial asked whether the oral GnRH antagonist DW4902 (160, 240, or 320 mg daily) could effectively control heavy menstrual bleeding in premenopausal women with uterine fibroids. In 71 women, 73–100% of DW4902 recipients achieved the primary endpoint of PBAC <10 during Weeks 6–12 (p<0.0001), with amenorrhea, fibroid volume reduction, and pain relief also improved. Adverse events were mostly mild, with modest, reversible lumbar spine bone density changes, supporting short-term safety and efficacy, though longer-term data are needed.

Jae-Yeon Song, Jung Yoon Park, Young Sik Choi, Dong-Yun Lee, Sung Eun Kim, Jung Ryeol Lee, Kyong Wook Yi, SiHyun Cho, Cho Chi-Heum, Miran Kim, Jong Kil Joo, Jung-Ho Shin, Sung Hoon Kim

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play